Phase I trial of DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine for solid malignancies including urothelial carcinoma (SPIRE)

Crabb, S.J., Danson, S. orcid.org/0000-0002-3593-2890, Catto, J.W.F. orcid.org/0000-0003-2787-8828 et al. (16 more authors) (2021) Phase I trial of DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine for solid malignancies including urothelial carcinoma (SPIRE). Clinical Cancer Research, 27 (7). pp. 1882-1892. ISSN 1078-0432

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2021 American Association for Cancer Research. This is an author-produced version of a paper subsequently published in Clinical Cancer Research. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Accepted: 15 January 2021
  • Published (online): 20 January 2021
  • Published: April 2021
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 12 Mar 2021 07:50
Last Modified: 11 Feb 2022 17:17
Status: Published
Publisher: American Association for Cancer Research (AACR)
Refereed: Yes
Identification Number: https://doi.org/10.1158/1078-0432.ccr-20-3946
Related URLs:

Share / Export

Statistics